Celgene Corporation
http://www.celgene.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Celgene Corporation
Finance Watch: 2024 Has Now Beaten 2023’s Total Of 21 IPOs
Public Company Edition: Upstream grossed $255m and CAMP4 raised $75m in October’s first initial public offerings. In follow-on offerings, Crinetics and Scholar Rock brought in $500m and $300m, respectively. Also, Turnstone cut 60% of its workforce and Gritstone filed for bankruptcy.
Clearside Clears Way For Phase III After Positive CLS-AX Results In Wet AMD
The company is developing the drug as a way to reduce injection burden for wet AMD patients and plans to meet with the US FDA early next year to discuss Phase IIb topline results.
Quarterly IPOs Climb Back Above $1bn
But biotechs are still having to price their offerings lower than they had planned.
Trial Of Kezar’s Only Active Drug Halted After Five Patients Die
The FDA has placed zetomipzomib on clinical hold a year after Kezar decided to focus solely on the product.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Technologies
- Bioinformatics
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Abraxis BioScience, Inc.
- AbVitro, Inc.
- Acetylon Pharmaceuticals, Inc.
- Avila Therapeutics, Inc.
- Delinia, Inc.
- EngMab AG
- Gloucester Pharmaceuticals, Inc.
- Impact Biomedicines, Inc.
- Juno Therapeutics, Inc.
- Juno Therapeutics GmbH (Stage Cell Therapeutics GmbH)
- JW Biotechnology (Shanghai) Co., Ltd
- Pharmion Corporation
- Quanticel Pharmaceuticals, Inc.
- Receptos, Inc.
- RedoxTherapies, Inc.
- X-BODY, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice